NKMAX Reveals Clinical Results of NK Cell Therapy for Non-Small Cell Lung Cancer at American Association for Cancer Immunotherapy Conference

Published 27 Sep.2021 10:24(KST)

[Asia Economy Reporter Hyungsoo Park] NK cell therapy developer NKMAX announced on the 27th that the abstract of its lung cancer clinical trial results submitted to the Society for Immunotherapy of Cancer (SITC) has been accepted and will be disclosed next month.

SITC is a global society with over 2,400 scientists, researchers, and clinicians from 42 countries worldwide engaged in cancer research and treatment. With the common goal of treating cancer patients, the academic conference for the development and advancement of immunotherapy will be held next month in Washington, USA.

NKMAX will present the results of its phase 1/2a clinical trial on non-small cell lung cancer conducted with the combination therapy of SuperNK (SNK01) + Keytruda (generic name: Pembrolizumab) at the SITC. This abstract is included in the program "The Evolution of Immunotherapy," which covers key topics in the fields of immunotherapy and cell therapy for cancer. The abstract details the final results of highly active NK cells cultured using NKMAX's unique technology against non-small cell lung cancer. Last year, NKMAX established the global position of its SuperNK by presenting excellent interim results at the ASCO conference.

Park Sang-woo, CEO of NKMAX, stated, "NKMAX is focusing on clinical trials for solid tumors, which constitute the majority of cancer types," and introduced, "The results are the final outcomes for lung cancer, which has the highest cancer mortality rate."

He added, "Following the previous results in sarcoma, it is significant that therapeutic effects were also observed in non-small cell lung cancer," and said, "Although data cannot be disclosed before the conference, SuperNK cell therapy is expected to be used for more solid tumors in the future."